-
Sector Analysis
Alzheimer’s Disease in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM.he US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2...
-
Sector Analysis
Parkinson's Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimated that the PD market was $3.3 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.2 billion, increasing at a compound annual growth rate (CAGR) of 7.9%. The major drivers of growth in the PD market will be the launch of several pipeline products including novel...
-
Sector Analysis
Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβ monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the...
-
Product Insights
Friedreich Ataxia: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Friedreich Ataxia - Global Clinical Trials Review, 2026" provides an overview of Friedreich Ataxia Clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Lennox-Gastaut Syndrome: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome - Global Clinical Trials Review, 2026" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035 The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and...
-
Sector Analysis
Narcolepsy: Epidemiology Report and Forecast to 2035
Narcolepsy is a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles, making people very sleepy during the day (Mayo Clinic, 2024; National Institute of Neurological Disorders and Stroke, 2026). Some patients also have other symptoms, such as muscle weakness when they feel strong emotions, which is known as cataplexy. Narcolepsy can disrupt daily life, making it hard to work, study, or maintain relationships. Narcolepsy is an uncommon but manageable lifelong condition (Cleveland Clinic, 2025). There are...
-
Product Insights
Spinal Muscular Atrophy (SMA) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Spinal Muscular Atrophy (SMA) - Global Clinical Trials Review, 2026" provides an overview of Spinal Muscular Atrophy (SMA) Clinical trials scenario. This report provides top line data relating to the clinical trials on Spinal Muscular Atrophy (SMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Dementia - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dementia - Global Clinical Trials Review, 2026" provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.